• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , Sept. 19

Arch Pharmalabs Ltd, a Mumbai-based company engaged in the manufacture of active pharmaceutical ingredients (APIs) and intermediates, has announced a co-marketing alliance with Apex Drugs & Intermediates Ltd, a Hyderabad-based company into APIs.

In a press release here, the Arch Pharmalabs Director, Mr V. Balaji, termed it as a new business model that the company is continuing to nurture. The company has been looking at such opportunities to help it expand its product and capabilities through partners thus exploring and banking on respective strengths in the manufacturing and marketing and offer the customers a single source for various products in various therapeutic segments, he said.

Apex Drugs said its association with Arch takes it to hitherto untapped markets.

Arch Pharmalabs said the Apex portfolio would help it to enter into the anti ulcerants, anti histamine and other therapeutic segments. It expects the pool of assets at Apex to aid it in restructuring the company's manufacturing and backward integration strategy.

Further, the Rs 250-crore Mumbai-based company said it is confident of similar alliances besides its organic growth strategy to help it consolidate its position in the CMO space in the pharma world.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Rajasthan refinery not viable: ONGC

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line